Newsroom | 2840 results

Sorted by: Latest

Veterinary
-

Sensorion annonce sa participation à la 49ème rencontre annuelle de l’Association pour la Recherche en Otorhinolaryngologie ARO

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce aujourd'hui sa participation à la 49ème rencontre annuelle de l'Association pour la Recherche en Otorhinolaryngologie (ARO), qui se tiendra du 7 au 11 février 2026 à San Juan, Porto Rico. Arnaud Giese, Ph.D., Responsabl...
-

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting, taking place on February 7-11, 2026, in San Juan, Puerto Rico. Arnaud Giese, Ph.D., Group Leader for Animal Pharmacology Platform at Senso...
-

Zoetis Declares Second Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovat...
-

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024): Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Dil...
-

Cencora Reports Fiscal 2026 First Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,...
-

Phibro Animal Health Corporation Declares Quarterly Dividend

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 25, 2026, to stockholders of record at the close of business on March 4, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with liv...
-

VMD Sciences Supports Veterinary Oncologist with Access to Advanced Cancer Treatment for Dog Through Global Managed Access

AUSTIN, Texas--(BUSINESS WIRE)--VMD Sciences, the leader in global veterinary pharmaceutical access services, announced the successful, compliant importation by a U.S. licensed veterinarian of an advanced cancer therapy approved in Europe. The specialized tyrosine kinase inhibitor unavailable in the U.S. was for the treatment of Jetta, an 8-year-old mixed-breed dog battling metastatic mast cell cancer. Through their Managed Access Program (MAP), VMD Sciences supported Dr. Seth Glasser, DVM, Dip...
-

BARK Retains Moelis & Company LLC as Financial Advisor to the Special Committee

NEW YORK--(BUSINESS WIRE)--BARK, Inc. (NYSE: BARK) (“BARK” or the “Company”), a leading global omnichannel dog brand with a mission to make all dogs happy, today announced that the special committee (the “Special Committee”) of the Company’s Board of Directors has retained Moelis & Company LLC as financial advisor and Sidley Austin LLP as legal advisor to assist the Special Committee in the review and evaluation of the previously disclosed preliminary non-binding indicative proposal letters...
-

BARK and Josh Horowitz Launch Who’s A Good Guest?, the Only Show Where Celebrities Are Upstaged by Their Dogs

NEW YORK--(BUSINESS WIRE)--BARK (NYSE: BARK), a leading global omnichannel dog brand on a mission to make all dogs happy, today announced the launch of Who’s A Good Guest?, a new video series hosted by entertainment journalist Josh Horowitz, produced by BARK and Horowitz. Season one features a star-studded lineup of dog parents, including Zoey Deutch, Dylan O’Brien, Bob Odenkirk, Johnny Knoxville, Ginnifer Goodwin, and Patrick Wilson. The first episode, featuring O’Brien and his dog Tony, debut...
-

IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. Fourth Quarter and Full Year Results The Company reports revenues of $1,091 million for the fourth quarter of 2025, an increase of 14% compared to the prior year period as reported and 12% on an organic basis, driven by Companion Animal Group ("CAG") growth of 15% as reported and 13% organic and Water revenue growth of 12...